Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunology
Research on cancer vaccines immunology described by scientists at University of Arizona, Research Center
May 20th, 2008
New research, 'Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression,' is the subject of a report. "CD4(+)CD25(+) regulatory T lymphocytes (Tregs) critically contribute to the mechanisms of cancer-induced tolerance. These cells suppress anti-tumoral CD8(+) and CD4(+) T lymphocytes and can also restrain the function of APCs," researchers in the United States report. "We have previously documented the immunostimulatory effects of a chaperone-rich cell lysate (CRCL) anti-cancer vaccine. Tumor-derived CRCL induces tumor immunity in vivo, partly by promoting dendritic cell (DC) and macrophage activation. In the...
Source: Cancer Weekly (2008-05-20)
|
